截至2026年2月5日 09:41，中证港股通医药卫生综合指数(930965)上涨0.32%，成分股银诺医药-B上涨 10.07%，药明康德上涨2.73%，海吉亚医疗上涨2.65%，再鼎医药上涨2.13%，四环医药上涨1.89%。港 股医药ETF(159718)下跌0.22%，最新报价0.92元。 消息面上，政策持续支持医药产业，国家药监局称，"十五五"期间将大力支持生物制造产业创新发展。 港股医药ETF紧密跟踪中证港股通医药卫生综合指数，中证港股通医药卫生综合指数从港股通范围内选 取50只流动性较好、市值较大的医疗卫生行业上市公司证券作为指数样本，以反映港股通范围内医药卫 生上市公司证券的整体表现。 数据显示，截至2026年1月30日，中证港股通医药卫生综合指数(930965)前十大权重股分别为药明生 物、百济神州、信达生物、康方生物、京东健康、石药集团、中国生物制药、翰森制药、药明康德、三 生制药，前十大权重股合计占比64.57%。 港股医药ETF(159718)，场外联接(平安中证港股医药ETF联接A：019598；平安中证港股医药ETF联接 C：019599；平安中证港股医药ETF联接E：024544 ...

港股一日游，低开低走后一路回撤，截至物品下跌0.61%。恒生互联网跌幅居前，恒生科技、恒生医疗等紧随其后，恒生银行逆势小涨。 恒生医疗低开低走，截至目前下跌2.12%，直逼前期低点。其中石油集团大跌2.83%，康方生物下跌2.48%，中国生物下跌2.37%，药明生物、药明康德、 翰森制药等多股跌幅均在2%上方。 恒生银行冲高回落，盘中一度上涨1.03%，截至目前上涨0.34%。其中青岛银行大涨4.78%，交通银行上涨2.25%，中国银行、重庆农村商业银行等股涨幅 均在1%上方；郑州银行、渣打银行、汇丰控股等均小幅下跌。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生互联网低开低走，截至目前大跌3.08%。其中商汤大跌3.73%，腾讯控股下跌3.7%，百度集团、地平线机器人、百度集团、快手、小米集团等超10只 个股跌幅在2%上方。 ...

Core Viewpoint - Hansoh Pharmaceutical (03692) announced the proposed issuance of HKD 4.68 billion zero-coupon convertible bonds maturing in 2033, with all conditions for the bond issuance having been met and successfully implemented on February 3, 2026 [1] Group 1 - The company has received approval for the listing and trading of the convertible bonds on the Hong Kong Stock Exchange [1] - The bonds are expected to be listed and traded on the Vienna MTF operated by the Vienna Stock Exchange on or around February 4, 2026 [1]

Core Viewpoint - Hansoh Pharmaceutical (03692) announced the proposed issuance of HKD 4.68 billion zero-coupon convertible bonds maturing in 2033, with all conditions for the bond issuance having been met and successfully implemented on February 3, 2026 [1] Group 1 - The company has received approval for the listing and trading of the convertible bonds on the Hong Kong Stock Exchange [1] - The bonds are expected to be listed and traded on the Vienna MTF operated by the Vienna Stock Exchange on or around February 4, 2026 [1]

本公告及其所載資料不會直接或間接於或向美國（包括美國的領土及屬地、任何州及哥倫比亞 特區）發佈。本公告及其所載資料並不構成在美國境內購買、認購或出售證券的任何要約或招 攬或其組成部分。本公告中所述的證券並無亦不會根據一九三三年美國證券法（經修訂）（「美國 證券法」）或美國的任何州或其他司法管轄區的證券法律登記。本公告中所述的證券將根據美國 證券法S規例（「S規例」）在美國境外發售和出售，除非已進行登記或獲豁免遵守美國證券法的 登記規定，否則該等證券不得在美國境內發售或出售。本公告中所述的證券將不會於美國境內 或該等發售受到限制或禁止的任何其他司法管轄區境內公開發售。本公告或其所載資料並非金 錢、證券或其他對價的招攬，而倘為回應本公告或其所載資料而寄出金錢、證券或其他對價， 將不會獲接納。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成提呈收購、購買或認購本公司證券之邀請或招攬，或訂立協議以作 出上述行動之邀請，亦不應被視為提呈 ...

致：香港交易及結算所有限公司 公司名稱: 翰森製藥集團有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03692 | 說明 | - | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.00001 | HKD | | 200,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.00001 | HKD | | 200,000 | 本月底法定/ ...

证券研究报告 | 行业简评报告 2026 年 02 月 03 日 布局消费反转！ 大消费组二月消费金股 研究部/消费品 % 1m 6m 12m 绝对表现 4.3 4.6 25.0 相对表现 3.1 -8.7 1.7 资料来源：公司数据、招商证券 -10 0 10 20 30 Feb/25 May/25 Sep/25 Jan/26 (%) 消费品 沪深300 相关报告 1、《招商证券 1 月港股消费观察： 外卖反垄断如何影响港股消费股前 景？》2026-01-27 2、《大消费组一月消费金股—双节 消费亮点前瞻》2026-01-06 ❑ 轻纺 杨蕊菁：看好家居板块修复以及倍加洁益生菌业务发展 风险提示：消费下行风险，消费复苏疲软风险、宏观经济变动风险等。 推荐（维持） 行业规模 | | | 占比% | | --- | --- | --- | | 股票家数（只） | 1216 | 23.5 | | 总市值（十亿元） | 17628.3 | 15.6 | | 流通市值（十亿元） | 16321.4 | 15.9 | 行业指数 3、《招商证券 12 月港股消费观察— 1-2 月流动性改善后港股消费买什 么？》2025 ...

恒生医疗低开低走三连跌，截至收盘下跌3.62%。 其中康方生物大跌8.61%，中国生物下跌5.27%，石药 集团下跌4.69%，百济神州下跌4.11%，京东健康、翰森制药、药明生物等股跌幅均在3%上方。 恒生银行探底回升，盘中一度大跌1.84%，截至收盘下跌1.05%。其中大新金融下跌3.54%，大新银行下 跌2.33%，重庆银行下跌2.29%，中银香港下跌2.04%，郑州银行、渣打银行、汇丰控股等超10只个股跌 幅在1%上方。 开盘后直线跳水，随后全天弱势，截至收盘大跌2.23%。恒生科技跌幅居前，互联网、恒生医疗、大消 费等紧随其后；恒生银行相对抗跌。 恒生科技低开低走大跳水，截至收盘下跌3.99%。比亚迪股份大跌6.91%，中芯国际下跌4.24%，百度集 团下跌3.99%，快手下跌3.93%，阿里巴巴下跌3.49%，网易下跌3.46%。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ ...

Core Viewpoint - Hansoh Pharmaceutical has been recognized for its outstanding performance in innovation, green production, environmental protection, social responsibility, and corporate governance, earning the title of "Green Leading Enterprise" and being included in the "Top 20 ESG Leading Samples" in Pudong New District's 2025 Environmental Performance Evaluation [1][4]. Group 1: Awards and Recognition - Hansoh Pharmaceutical is the only Chinese pharmaceutical company recognized as a "Green Leading Enterprise" among the evaluated entities [1][4]. - The "2025 ESG Leading Samples" evaluation was guided by various organizations, including the Shanghai Modern Service Industry Association and the Pudong New District Business Committee, with support from the Ministry of Commerce [2][5]. - The company has received high recognition from global authoritative institutions, maintaining an MSCI AA rating for several years and being listed in the S&P Global "Sustainability Yearbook" as one of the top 1% in the industry [3][6]. Group 2: ESG Practices and Contributions - Hansoh Pharmaceutical has significantly improved diagnostic capabilities and created social welfare in the treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD), which contributed to its selection in the "Top 20 ESG Leading Samples" [2][5]. - The Pudong New District has been enhancing its ESG evaluation system, encouraging enterprises to align with international standards and systematically improve their environmental, social, and governance development levels [2][5]. - As a key enterprise in the region, Hansoh Pharmaceutical actively participates in and shares its ESG practices, providing valuable examples and development paths for the pharmaceutical and related industries [2][5]. Group 3: Environmental Information Disclosure - In the 2025 Environmental Information Disclosure Ratings released by the global authoritative platform CDP, Hansoh Pharmaceutical achieved a dual B rating in climate change and water security, maintaining a leading position among Chinese pharmaceutical companies [3][7].

Group 1: Technology and AI - Alphabet (GOOGL US) is expected to maintain good visibility in its advertising business due to the gradual release of its valuation under pressure from AI search, with a projected cloud business growth rate of over 30% for the year [1] - Alibaba (BABA US) is anticipated to see a cloud business growth rate of 28%-30%, driven by strong demand in China, with significant contributions from its instant retail segment [1] - NVIDIA (NVDA US) is projected to achieve revenue exceeding 500 billion, with strong growth expected from its GB300 product line, which constitutes two-thirds of the Blackwell series [1] Group 2: E-commerce and Internet Services - Tencent (700 HK) is recommended as a top pick due to its strong investment in AI and steady growth in its core gaming and advertising businesses, with a target price of 700 [1] - Tencent Music (TME US) is expected to maintain a stable growth trajectory with a focus on subscription and non-subscription revenue streams, despite some margin pressure from new business initiatives [1] - Kuaishou (1024 HK) is projected to see significant revenue growth driven by its AI-enhanced content ecosystem, with a target price of 93 [2] Group 3: Healthcare and Pharmaceuticals - New Oxygen (SY US) is positioned well in the light medical beauty sector, with plans to expand its self-operated stores significantly by 2025, supported by a strong marketing capability and low customer acquisition costs [2] - Hansoh Pharmaceutical (3692 HK) is focusing on expanding its pipeline in oncology and other major indications, with a strong emphasis on innovative drug development [3] - BeiGene (6160 HK) is expected to exceed management's revenue guidance for 2025, driven by strong sales of its BTK inhibitor, with a projected peak sales potential of over 8 billion [4] Group 4: Energy and Materials - Saudi Aramco (ARAMCO AB) is positioned as a central player in global energy supply, with ongoing investments in hydrogen and carbon capture technologies, enhancing its long-term growth prospects [6] - MP Materials (MP US) is the only company in the U.S. with a fully scaled rare earth supply chain, benefiting from strong demand in the defense and renewable energy sectors [6] - Howmet Aerospace (HWM US) is expected to maintain a strong market position in gas turbine components, with a long order backlog supporting stable revenue growth [5]